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Abstract
Background: To determine if oral metronidazole (MTZ-400mg bid) with 2% vaginal clindamycin-cream (Clind) or a
Lactobacillus acidophilus vaginal-probiotic containing oestriol (Prob) reduces 6-month bacterial vaginosis (BV) recurrence.
Methods: Double-blind placebo-controlled parallel-group single-site study with balanced randomization (1:1:1) conducted
at Melbourne Sexual Health Centre, Australia. Participants with symptomatic BV [Nugent Score (NS)=7–10 or $3 Amsel’s
criteria and NS=4–10], were randomly allocated to MTZ-Clind, MTZ-Prob or MTZ-Placebo and assessed at 1,2,3 and 6
months. MTZ and Clind were administered for 7 days and Prob and Placebo for 12 days. Primary outcome was BV recurrence
(NS of 7–10) on self-collected vaginal-swabs over 6-months. Cumulative BV recurrence rates were compared between
groups by Chi-squared statistics. Kaplan-Meier, log rank and Cox regression analyses were used to compare time until and
risk of BV recurrence between groups.
Results: 450 18–50 year old females were randomized and 408 (91%), equally distributed between groups, provided $1N S
post-randomization and were included in analyses; 42 (9%) participants with no post-randomization data were excluded.
Six-month retention rates were 78% (n=351). One-month BV recurrence (NS 7–10) rates were 3.6% (5/140), 6.8% (9/133)
and 9.6% (13/135) in the MTZ-Clind, MTZ-Prob and MTZ-Placebo groups respectively, p=0.13. Hazard ratios (HR) for BV
recurrence at one-month, adjusted for adherence to vaginal therapy, were 0.43 (95%CI 0.15–1.22) and 0.75 (95% CI 0.32–
1.76) in the MTZ-Clind and MTZ-Prob groups compared to MTZ-Plac respectively. Cumulative 6-month BV recurrence was
28.2%; (95%CI 24.0–32.7%) with no difference between groups, p=0.82; HRs for 6-month BV recurrence for MTZ-Clind and
MTZ-Prob compared to MTZ-Plac, adjusted for adherence to vaginal therapy were 1.09(95% CI=0.70–1.70) and 1.03(95%
CI=0.65–1.63), respectively. No serious adverse events occurred.
Conclusion: Combining the recommended first line therapies of oral metronidazole and vaginal clindamycin, or oral
metronidazole with an extended-course of a commercially available vaginal-L.acidophilus probiotic, does not reduce BV
recurrence.
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Bacterial vaginosis (BV) is the commonest cause of abnormal
vaginal discharge in women of reproductive age, with a prevalence
of 29% in 17–49 year old North American women [1]. First line
therapies include a week of oral metronidazole or vaginal
clindamycin cream, or 5 days of vaginal metronidazole gel, and
all have similar short-term efficacy [2,3]; however, long term BV-
recurrence following these therapies is common, with rates as high
as 58% within 12 months of oral metronidazole [4].
Unacceptably high BV-recurrence rates after monotherapy, and
differing antibiotic susceptibilities of BV-associated bacteria, led
researchers to investigate whether combining oral metronidazole
and vaginal clindamycin was more effective than metronidazole
monotherapy. An alternative or complementary approach to the
use of antibiotics is the use of lactobacillus-probiotics to help
restore the healthy vaginal ecosytem. A recent Cochrane review
highlighted the need for large randomized placebo-controlled
trials with standardized outcomes in this area [5]. We chose a
commercially available vaginal-probiotic containing Lactobacillus
acidophilus KS400 and 0.03 mg of oestriol to evaluate with
metronidazole. The probiotic had demonstrated efficacy against
BV in two studies, and shown normalization of vaginal flora with
an increase in lactobacillus-scores in women with a BV when used
after antimicrobial therapy [6,7]. The inclusion of oestriol in the
product is supported by the protective effect against BV observed
in women using combined hormonal contraceptives such as the
oral contraceptive pill and NuvaringH in observational studies
[4,8,9,10,11].
The aim of our study was to determine whether the
combination of oral metronidazole with either 2% vaginal
clindamycin cream or a commercially-available vaginal-probiotic
reduced rates of BV-recurrence over 6 months compared to oral
metronidazole with a vaginal-placebo.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Trial Design
This was a double-blind placebo-controlled parallel-group study
with balanced randomization (3 arms 1:1:1) conducted in
accordance with the original protocol in a single site in Melbourne,
Australia.
Participants
Recruitment was conducted from December 2007 to May 2010
at the Melbourne Sexual Health Centre (MSHC). Eligible
participants were 18–50 year old females with symptomatic BV,
defined as abnormal vaginal discharge or odour with a Nugent
Score (NS) of 7–10 or $3 Amsel’s criteria and a NS of 4–10.
Women were ineligible if they were: HIV positive, pregnant,
breastfeeding, attempting to conceive, not fluent in English,
without an Australian-postal address, and not able to abstain from
vaginal sex during vaginal therapy if they were reliant on 100%
condom use for STI protection/contraception. The mineral oil in
clindamycin cream has been reported to affect condom integrity
(Pfizer, Australia).
Symptomatic BV-positive women were examined by a clinician
who recorded clinical signs and collected a high-vaginal swab for a
vaginal wet-preparation and Gram-stained smear. The smear was
scored by Nugent criteria in an onsite laboratory, and Amsel’s
criteria were recorded. Women were screened for Chlamydia
trachomatis by Strand-displacement amplification (BD ProbeTec
ET CT-Amplified DNA Assay, Becton-Dickinson & Co,
MD,USA), Neisseria gonorrhoeae by culture of endocervical swabs
(modified Thayer-Martin medium), Trichomonas vaginalis by wet
preparation and culture of vaginal swabs (modified Diamonds
medium) and Candida spp. by microscopy and culture. Women
were referred to the research nurse, who obtained written
informed consent from eligible participants. Participants self-
completed a questionnaire on demographic, clinical and behav-
ioural characteristics during the recruitment interview.
Interventions
Participants received 400 mg twice daily of oral metronidazole
for 7 days, and were randomly assigned to a vaginal intervention
(placebo, clindamycin, or probiotic). Vaginal 2% clindamycin
cream was in a plain white tube and prescribed as one applicator
vaginally for 7 nights. The probiotic and placebo were prescribed
as a single vaginal pessary for 12 nights in keeping with the
manufacturer Medinova’s (Switzerland) recommendations and
freely-donated. The probiotic contained at least 10
7 colony
forming units (CFU) of live L.acidophilus KS400, 0.03 mg oestriol
and excipients. The vaginal-placebo preparation was identical in
appearance to the probiotic, and contained only excipients.
Vaginal preparations were packed according to the allocation
sequence by a nurse with no other involvement in the study in
sequentially-numbered opaque cardboard boxes. Samples were
taken from the probiotic and placebo batches that were given to
participants, and were cultured at two time points during the
study. Under the same culture conditions, we confirmed no
growth of bacteria in the placebo, and viability of $10
7 CFU of
live L.acidophilus but no growth of other bacteria in the probiotic.
Outcomes
The primary outcome measure was recurrence of BV (NS 7–10)
within six months, assessed at 1, 2, 3 and 6 months following the
intervention by participant self-collected vaginal-smears. The use
of self-collected samples for the diagnosis of BV has been shown to
be comparable to clinician-collected samples [12,13]. The
secondary outcome measure was recurrence of abnormal
vaginal-flora (NS 4–10). One of three blinded microscopists
experienced in Nugent’s methodology scored vaginal smears.
Difficult to interpret slides were independently reread by the
second then third microscopist until consensus was reached. In an
audit during the trial, the three microscopists achieved $92%
concordance in Nugent scoring a sample of 40 vaginal Gram-
stained smears representing all Nugent categories. Participants
were informed when they reached the primary endpoint (NS 7–10)
and offered re-treatment with either metronidazole or clindamy-
cin.
Sample Size
We estimated a 6 month BV recurrence rate of 50% in the oral
metronidazole/vaginal-placebo arm from previous work [4]. To
detect a 20% reduction in BV recurrence with either active vaginal
therapy compared to placebo, with a two-sided 5% significance
level and 90% power, a sample size of 123 was required for each
group. Assuming 20% loss to follow-up, 150 women were
recruited to each treatment group.
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and Blinding
Participants were randomly assigned to one of three study arms
in blocks of 15 using a computer-generated sequence. The
sequence was produced by a statistician with no clinical input
into the trial and securely held by the statistician and nurse
packing the vaginal therapies in sealed boxes. At enrolment a
research nurse, with no access to the randomization schedule, gave
each woman the next sequentially-numbered sealed box according
to the random number sequence. Specific instructions for use of
vaginal products were inside the sealed box, which participants
were instructed to open at home. They were told their vaginal
treatment may be an antibiotic, placebo or probiotic, that it may
be a cream or pessary, and that the duration of use may be 7 or 12
days, but given no further product details. The participants, the
research nurse co-ordinating enrolment and retention of study
participants, investigators and microscopists were unaware of the
participants’ group allocation. The effectiveness of blinding was
tested at completion of the trial when participants were asked to
indicate in their questionnaire which vaginal treatment they
thought they had received.
A data safety and monitoring board was not deemed necessary.
Trial products had been licensed for use in Europe and/or North
America, there is extensive community experience with oral
metronidazole and vaginal clindamycin, and significant adverse
events were considered unlikely. Participants were aware that they
could attend MSHC or call a free investigator-staffed number for
clinical queries seven days a week.
Follow-up and retention
At each follow-up, participants were posted a kit containing a
questionnaire, self-swabbing instructions, an encased-Dacron swab
and glass slide to self-smear. Participants who developed symptoms
between scheduled follow-ups were encouraged to call the free
number staffed by investigators and to have interim samples
collected, or to attend our clinical service. To optimize retention,
participants were contacted by email or telephone upon kit
postage and on three consecutive weekly occasions if the kit was
not returned. Outcome data were deemed missing if not returned
by halfway through the follow-up interval, or at 6 months if .210
days after enrolment, to allow sufficient time for return of final
specimens/questionnaires. Participants who did not return
specimens after these time points were deemed lost to follow-up
and censored at their last returned-specimen.
Statistical methods and ethics approval
Data were entered and stored in Microsoft Access and analysed
using SPSS 17.0 (SPSS Inc.,Chicago,IL,USA) and STATA 9.0
(StataCorp,2005).. Participants were excluded if no post-random-
ization data was available, and individuals providing post-
randomization data who were subsequently lost to follow-up,
were analysed according to the last Nugent score available.
Cumulative recurrence of both BV and abnormal flora was
determined for each treatment group and the overall study
population. Proportions were compared using Chi-square and
Fisher’s Exact tests where appropriate, and 95% confidence
intervals (CIs) were calculated. All statistical tests were two-sided
and a level of p,0.05 was considered significant. Kaplan-Meier
methods were used to generate survival curves for time until
recurrence of BV and abnormal vaginal-flora, and log rank
analysis was used to compare survival curves between groups. Cox
regression analysis was used to generate hazard ratios for risk of
BV-recurrence. Multivariate analysis was performed to account
for any differences in baseline characteristics between treatment
groups, and for factors known to be clinically-associated with BV-
recurrence. Longitudinal factors associated with BV-recurrence
among trial participants will be explored in a subsequent paper.
Data were censored when participants either had BV-recurrence,
reached study endpoint at 210 days, or were deemed lost to follow-
up, as previously described. This trial received ethics approval
from the Human Research and Ethics Committees of the Alfred
Hospital and Monash University, Melbourne, Australia, and
written informed consent was obtained from all participants. The
trial was registered at the Australian New Zealand Clinical Trials
Registry [ACTRN12607000350426].
Results
Participant flow and recruitment baseline data
From November 2007 to May 2010, there were 1282 MSHC
attendees with a diagnosis of BV, of which 448 (35%) were not
eligible. Of the 834 remaining women with BV: 103 (12%) were
not asked to participate, 281 (34%) declined and 450 (54%) agreed
to participate, Figure 1. The demographic and behavioural
characteristics of known eligible participants (n=450) and non-
participants (n=384) were compared. Non-participants were more
likely to be sex workers (32% versus 17%, p,0.01), to be
Australian (66% versus 49%, p,0.01) and to report 100%
condom use in the prior 3 months (15% versus 5%, p,0.01);
indicating many non-participants relied on consistent condom use,
and would be likely to have been deemed ineligible if referred to
the research nurse. Of the 450 participants: 382 (85%) had a NS of
7–10 and 68 (15%) had 3–4 Amsel’s criteria and a NS of 4–6.
All 450 participants were randomly assigned to and received
their allocated treatment and no cross-over of treatments or
imbalance in allocation occurred. There were no substantial
differences between the three treatment groups in any demo-
graphic or behavioural characteristics, Table 1. Follow-up of
participants occurred from November 2007 to December 2010,
Figure 1.
Numbers analysed
Participants were analysed according to their randomized
groups. Forty-two participants provided no post-randomization
data were not included in analyses. The primary and
secondary analyses therefore involved all participants provid-
ing post-randomization NS data [n=408 (91%)], Figure 1. Of the
42 women who provided no post-randomization data, 30 were lost
to follow-up and 12 withdrew; most gave no reason for
withdrawal, although three stated they did not take medication.
Those not included were equally distributed between groups
(p=0.35) and were more likely to be smokers (69% compared to
44%, p=0.003), but there were no other significant demographic
or behavioural differences (data not shown P.0.13). Fifty-seven
participants (13%) were lost to follow-up before reaching 6-months
or developing recurrence (NS=7–10) and were equally distributed
between groups; six month retention rates were therefore 78%
(n=351). These 57 participants all had a NS,7 at last observation
and contributed person-time to the survival analyses as non-
recurrent cases on the basis of their last Nugent score. The same
408 women were included in the secondary analysis where the
endpoint was abnormal vaginal-flora (NS=4–10).
Concurrent medications and genital infections at
baseline
Concurrent medications prescribed at baseline by referring
clinicians occurred at similar rates between groups, Table 2. Fifty-
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(6%) on microscopy. STI screening of participants at baseline
(94%) revealed 25 (7%) had chlamydia, and 2 (0.5%) had
gonorrhoea, and none had trichomoniasis. There were no
differences in STIs or candidiasis between the groups.
Self-reported adherence to trial medication and vaginal-
product concealment
Self-reported adherence to oral metronidazole was high; $92%
of participants took ‘‘all/nearly all’’ with no difference between
study groups, Table 2. Self-reported adherence was higher to
clindamycin (88%) compared to the other two groups (77–78%)
when assessed as ‘all/nearly all’ (p=0.04). Participants were asked
to tick which vaginal product they thought they had received or
‘‘don’t know’’ at completion of the trial; 87% of participants either
did not know or incorrectly guessed the vaginal medication that
they had received.
Interim antibiotic use during follow-up in the community
Interim oral and vaginal therapies were commonly self-
reported. Possible community-use of metronidazole (n=10) was
self-reported, none in the probiotic-group (0%) compared to 4.3%
in the clindamycin and 2.9% in the placebo groups, p=0.05,
Table 3. Metronidazole was prescribed at MSHC for 17
participants with clinical features of BV but a NS of 4–6.
Combined community and clinic metronidazole use (n=27) did
Figure 1. Participant Flow.
doi:10.1371/journal.pone.0034540.g001
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difference in reported use of vaginal treatments between treatment
arms; the majority were antifungals, with clindamycin cream
uncommonly reported.
Outcomes and estimation
Primary Outcomes. The 408 women included in the
primary analysis contributed 112.5 person years (py) of follow-
up. There was no difference in observed follow-up between the
treatment groups (placebo 39.8 py, clindamycin 39.8 py and
probiotic 43 py), p=0.94. One month BV recurrence (NS 7–10)
rates were 3.6%, 6.8% and 9.6% in the clindamycin, probiotic and
placebo groups respectively, p=0.13, table 4. Hazard ratios (HR)
for BV recurrence at month were 0.40 (95% CI 0.14–1.10) for the
clindamycin arm and 0.74 (95% CI 0.32–1.74) for the probiotic
arm compared to placebo, p=0.08. The clindamycin group was
significantly more adherent to the vaginal product (when assessed
as taking all or most of the product) compared to the probiotic and
placebo groups, 88% compared to 77–78% (p=0.04). Neither
treatment group was significantly more effective at reducing BV
recurrence at one month than the placebo group, after adjustment
for adherence to the vaginal product, [clindamycin HR=0.43
(95% CI 0.15–1.22) and probiotic HR=0.75 (95% CI 0.32–
1.76)].
Table 1. Basic demographic and behavioural characteristics of study population (n=450:150 participants per arm).
Treatment Arm of Clinical Trial
Characteristic
Metro
a/clinda
b
n (% or range)
Metro
a/probiotic
c
n (% or range)
Metro
a/placebo
c
n (% or range)
Median Age (range) yrs 27 (17–49) 27 (17–47) 27 (18–49)
Ethnicity
d
Australian/British 100 (67) 106 (71) 106 (72)
Other 50 (33) 44 (29) 42 (28)
Educational level
Primary &/or Secondary 49 (34) 51 (34) 49 (35)
Tertiary 94 (66) 97 (66) 92 (65)
Past history of BV
No 76 (52) 69 (46) 83 (58)
Yes 69 (48) 80 (54) 61 (42)
Median Lifetime MSPs (range) 11 (0–400) 12 (0–300) 10 (0–200)
Median Lifetime FSPs (range) 0 (0–50) 0 (0–40) 0 (0–66)
Any new MSP last 12 months
No 39 (27) 47 (31) 40 (28)
Yes 104 (73) 101 (69) 102 (72)
Any new FSP last 12 months
No 123 (85) 115 (79) 127 (86)
Yes 23 (15) 30 (21) 21 (14)
Current RSP at time of randomization
No 38 (25) 55 (37) 53 (36)
Yes 112 (75) 94 (63) 96 (64)
Current sex work
No 127 (85) 123 (82) 118 (89)
Yes 22 (15) 27 (18) 32 (21)
Current smoker
No 83 (57) 74 (50) 83 (56)
Yes 62 (43) 75 (50) 65 (44)
Current use of a hormonal method of contraception
e
No 96 (64) 99 (66) 107 (72)
Yes 54 (36) 50 (34) 42 (28)
aMetro=oral metronidazole 400 mg twice daily for 7 days,
bclinda=one applicatorful of 2% vaginal clindamycin cream nightly for 7 nights,
cplacebo and probiotic=vaginal pessary for 12 nights,
dAus/UK ethnicity=identify as either Australian or British, other ethnicity comprised predominantly of individuals from South East Asia, China, Northern Europe and
North America,
ehormonal contraception=oral contraceptive pill, implants such as implanon, Depo-ProveraH and hormonal rings such as NuvaringH, MSP=male sexual partner,
FSP=female sexual partner, RSP=regular sexual partner. Missing data for specific variables for #5% of participants. Missing data excluded from the analysis and
proportions are calculated from available data. Proportion with missing data did not differ between arms.
doi:10.1371/journal.pone.0034540.t001
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rate of 28.2% (24.0–32.7%) and no difference between the
treatment arms (p=0.82; Table 4). Figure 2 depicts the Kaplan-
Meier survival analysis with no difference between treatment
groups (log rank test, p=0.93). The unadjusted HR for BV-
recurrence for vaginal clindamycin and the vaginal probiotic
compared to placebo were 1.09 (95% CI 0.70–1.70) and 1.02
(95% CI 0.64–1.61), respectively. When adjusted for adherence to
vaginal therapy as previously defined, the HRs for BV recurrence
at six months compared to placebo were unchanged at 1.09 (95%
CI 0.70–1.70) for vaginal clindamycin and 1.03 (95% CI 0.65–
1.63) for the vaginal-probiotic.
Secondary Outcomes. Four hundred and eight women were
included in the secondary analysis. One month and cumulative 6-
month recurrence rates for abnormal vaginal-flora (NS 4–10) were
23% (95%CIs 19–27%) and 54% (95% CIs 49–59%), respectively,
and did not differ between treatment groups (p=0.87; Table 4).
The HRs for one and six month BV recurrence, adjusted for
adherence to vaginal therapy, are shown in table 4, and at each
time point neither treatment group was superior to placebo.
Figure 3 depicts the Kaplan-Meier survival analysis, again with no
difference between treatment groups (log rank p=0.96).
Adverse Events
Self-reported adverse effects are shown in Table 3. One third of
participants reported vaginal itching/soreness and 8% reported
nausea; all other side effects were uncommon or rare and the only
adverse symptom that significantly differed between treatment
groups was increased vaginal discharge, which was reported by
more participants in the probiotic group (p=0.006).
Discussion
This RCT shows that 7 days of oral metronidazole combined
with 2% vaginal clindamycin cream or a 12 day course of a
commercially- available vaginal L. acidophilus probiotic does not
achieve higher cure rates for BV compared with oral metronida-
zole monotherapy over six months of follow-up. These findings
suggest that combining first line regimens and achieving broader
spectrum antibiotic coverage does not improve the clinical
outcome above a standard course of oral metronidazole.
This is the first placebo-controlled RCT to evaluate the effect of
combining oral metronidazole with vaginal clindamycin. These
regimens have been shown to have equivalent clinical efficacy as
monotherapy with one month cure rates of 80% [3], despite
differing spectrums of antimicrobial activity. Metronidazole is
active against anaerobes, whereas clindamycin has broader
spectrum activity against Gram-positive aerobes and anaerobes.
The microbial flora pattern following treatment with clindamycin
differs to metronidazole, with greater reduction in Mobiluncus spp
and higher frequency of clindamycin-resistant anaerobes
[14,15,16]. Meltzer also confirmed the relative resistance of
Mobiluncus spp to metronidazole therapy, and showed their
persistence was associated with increased risk of BV recurrence
[17]. Based on these data and the polymicrobial nature of BV, one
might postulate that higher cure rates could be reached by
combining metronidazole and clindamycin. The combination has
the potential to achieve i) broader spectrum activity against
possible aetiological agents and other BV-associated bacteria that
may contribute to symptomatology and sequelae, ii) reduction in
the selection of macrolide-resistant species, and iii) high concurrent
vaginal and systemic levels of antibiotic to promote more effective
clearance of BV-associated bacteria. Conversely, combination
Table 2. Concurrent medications and self-reported adherence to trial medication (n=408).
Concurrent medications prescribed at baseline to participants
Clindamycin Arm n=140 (%)Probiotic Arm n=133 (%) Placebo Arm n=135 (%) P value
Oral fluconazole* 23 (16.4) 22 (16.5) 21 (15.5) 0.97
Doxycycline* 4 (2.9) 2 (1.5) 4 (3.0) 0.69
Azithromycin* 18 (12.9) 10 (7.5) 18 (13.3) 0.25
Ceftriaxone* 2 (1.4) 1 (0.8) 3 (2.2) 0.70
Antivirals 2 (1.4) 4 (3.0) 2 (1.5) 0.61
Other antibiotics 3 (2.1) 7 (5.3) 5 (3.7) 0.36
Vaginal antifungal 2 (1.4) 1 (0.8) 0 0.66
Self-reported adherence to oral and vaginal therapies by treatment group
Clindamycin Arm n=140 (%) Probiotic Arm n=133 (%) Placebo Arm n=135 (%) P value
Self reported adherence to
metronidazole
All/nearly all tablets taken 127 (93) 120 (92) 124(92) 0.91
$50% tablets taken 133 (97) 128 (99) 130 (96) 0.86
No tablets taken 1 (1) 1 (1) 1 (1) 1.0
Self reported adherence to
vaginal therapy
All/nearly all product used 121 (88) 100 (77) 104 (78) 0.04
$50% product used 130 (95) 115 (89) 119 (89) 0.20
No product used 3 (2) 8 (6) 4 (3) 0.27
*Fluconazole prescribed as 150 mg stat dose, doxycycline as 100 mg bid for 7 days, azithromycin as 1 g stat dose and ceftriaxone as 500 mg IM.
doi:10.1371/journal.pone.0034540.t002
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found no therapeutic benefit from combining first line therapies,
but also no increase in adverse symptoms, particularly symptom-
atic candidiasis, in the combination antibiotic arm. Importantly,
ongoing analysis will assist in determining whether any behav-
ioural factors play a significant role in recurrence following
treatment.
This trial also tested the efficacy of combining a 12-day course
of a commercially available vaginal-probiotic containing
$10
7 CFU of live L. acidophilus and 0.03 mg oestriol with oral
metronidazole, and found no benefit over metronidazole mono-
therapy. This product demonstrated improved restoration of
normal vaginal-flora in two studies in BV-positive women [6,7]. In
a placebo-controlled RCT of 32 women diagnosed with BV by the
Amsel method, Parent found 6 nights of the probiotic achieved
two and four week cure rates of 77% and 88% compared to 25%
and 22% in the placebo group, respectively, p,0.05 [7]. A
statistically significant increase in Lactobacillus spp on Gram-stain
was recorded in the treatment compared to the placebo group at
two and four weeks, p,0.05. In a randomized-blinded placebo-
controlled trial of 366 women, Ozkinay reported a statistically
significant improvement in the normal-flora-index (a composite of
lactobacillus count, vaginal pH, leucocytes and pathogenic micro-
organisms) of women with BV, candidiasis or trichomoniasis
following anti-infective therapy and 12 nights of vaginal-probiotic
compared to placebo, p,0.002 [6].
Probiotic therapies are emerging as popular over-the-counter
treatments for vaginal candidiasis and BV. As loss of Lactobacillus
spp in the vagina is a characteristic of BV, it is thought that
lactobacillus-probiotics may support restoration of the normal
lactobacillus-dominant state. Several vaginal Lactobacillus spp have
host protective characteristics, including hydrogen peroxide, lactic
acid and biosurfactant production, antimicrobial activity, and
coaggregation with pathogens [18,19]. While a considerable
Table 3. Interim antibiotic use and self-reported side effects to trial medications (n=408).
Self-reported antibiotic use in the community during follow-up
Study Population
n=408 (%)
Clindamycin Arm
n=140(%)
Probiotic Arm n=133
(%)
Placebo Arm n=135
(%) P value
Oral metronidazole 10 (2.5) 6 (4.3) 0 4 (2.9) 0.05
Oral macrolide 15 (3.7) 7 (5.0) 4 (3.0) 4 (2.9) 0.67
Oral tetracycline 5 (1.2) 3 (2.1) 1 (0.8) 1 (0.7) 0.63
Oral penicillin or
cephalosporin
23 (5.6) 10 (7.1) 6 (4.5) 7 (5.2) 0.64
Other unknown oral
therapy*
99 (24.3) 42 (30) 30 (22.6) 27 (20) 0.14
Vaginal antifungal 67 (17.0) 34 (24.3) 21 (15.8) 23 (17) 0.16
Vaginal clindamycin 2 (0.5) 1 (0.7) 0 1 (0.7) 0.77
Other unknown vaginal
therapy{
19 (4.7) 10 (7.1) 5 (3.8) 4 (2.9) 0.27
Interim metronidazole prescribed at Melbourne Sexual Health Centre during follow-up
Oral metronidazole 17 (4.7) 4 (2.9) 6 (4.5) 7 (5.2) 0.58
Self-reported side effects to trial medication
Study Population
n=408 (%)
Clindamycin Arm
n=140 (%)
Probiotic Arm n=133
(%)
Placebo Arm n=135
(%) P value
Vaginal itch/soreness 123/378 (33) 41/130 (32) 43/121 (36) 39/127 (31) 0.82
Nausea 30/372 (8) 9/126 (7) 5/118 (4) 16/128 (13) 0.06
Vomiting 2 (0.5) 0 1 (0.8) 1 (0.8) 0.77
Abdominal Pain 4 (1.1) 1 (0.7) 1 (0.8) 2 (1.6) 1.0
Diarrhoea 1 (0.3) 1 (0.7) 0 0 1.0
Headache 7 (1.9) 5 (3.7) 1 (0.8) 1 (0.8) 0.21
Metallic Taste 9 (2.4) 5 (3.7) 3 (2.3) 1 (0.8) 0.23
Body rash 2 (0.5) 0 1 (0.8) 1 0.33
Increased VD 7 (1.9) 0 6 (4.7) 1 (0.8) 0.006
VD containing medication 4 (1.1) 1 (0.7) 2 (1.6) 1 (0.8) 0.70
UTI 3 (0.8) 0 2 (1.6) 1 (0.8) 0.32
Possible PID 1 (0.3) 0 0 1 (0.8) 1.0
Genital HSV 1 (0.3) 0 0 1 (0.8) 1.0
VD=vaginal discharge, UTI=urinary tract infection, PID=pelvic inflammatory disease, HSV=herpes simplex.
virus. Data available from the month one questionnaires for 367–395 (90–96%) participants for specific side effects. Proportion with missing data did not differ between
arms. Denominators used to calculate proportions with side effects in each treatment group reflecting available and not missing data.
*Unknown oral therapies may have been antibiotics or oral antifungals and could not be verified,
{likely to have represented vaginal antifungal agents but could not be substantiated.
doi:10.1371/journal.pone.0034540.t003
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species in the probiotics have varied substantially in their
characteristics, their ability to colonise the vagina [20], and
adherence to vaginal epithelial cells [21]. A 2009 Cochrane review
found that only 4 RCTs, including the trial by Parent [7], met the
inclusion criteria for a systematic review [5], and substantial
heterogeneity in products, trial methodologies and outcome
measures meant that there was insufficient evidence to establish
the role of probiotics in BV. More recent observational data using
prolonged repetitive courses of lactobacillus-probiotics appear to
show more promise than short courses [22,23,24]. Another
important advance in the field has been the development of a
probiotic containing a human hydrogen-peroxide producing L.
crispatus, which appears acceptable and safe in early studies
[25,26]. However, large-scale well-designed clinical trials with
standardized outcomes to enable direct comparison between
probiotics is a priority to advance the field [5].
An important limitation of this trial was that the products and
formulations could not be identical in duration and appearance.
Clindamycin ovules are not available in Australia so investigators
used the cream. The probiotic could only be obtained as a pessary
and the decision was made to match the placebo to this pessary.
Considerable care was therefore taken with concealment of the
nature of the vaginal therapy. Participants were not given any
trade-names or information to enable them to link a product with
its appearance or duration of therapy, and the placebo could not
be distinguished from the probiotic. Trial medications were in
plain packaging, sealed in opaque boxes and participants were
instructed to open their kits at home. No study staff had access to
the randomization schedule and the primary and secondary
outcome of the trial was the Nugent score, determined by blinded
microscopists with no access to any other trial data. We considered
87% of participants not knowing or incorrectly guessing which
vaginal medication they had received as evidence of successful
concealment.
Another important aspect of the trial was that the Nugent
method was used to assess the endpoint of BV as it is widely
considered to be the most objective diagnostic measure, is relevant
and generalizable to clinical trials, and is suited to extended follow-
up in the community. The limitation of this approach is that some
participants with symptoms of BV, but intermediate flora, were
considered as non-recurrent on the basis of the strict Nugent
criteria defined primary outcome (NS 7–10); these cases were
counted as recurrent cases in the secondary analysis of abnormal
flora. The use of the Nugent method is therefore likely to result in
an under-estimation of the recurrence rate of clinically-evident
Table 4. Recurrence Rates and Relative Risk of Recurrence of BV and of Abnormal flora at Month one and Month six by Treatment
Group (n=408){.
Primary Study Outcomes by Treatment Arm
Treatment Arms
Clindamycin n=140
(%, 95%CIs)
Probiotic n=133
(%, 95% CIs)
Placebo n=135
(%, 95% CI)
Study Population n=408
(%, 95% CI)
M1 BV recurrence rate* 5/140 (3.6, 1.3–7.7) 9/133 (6.8, 3.4–12.1) 13/135 (9.6, 5.4–15.5) 27/408 (6.6, 4.5–9.4)
Hazard ratio for M1 BV
recurrence compared to
placebo{
0.43 (0.15–1.22) 0.75 (0.32–1.76) - -
Cumulative M6 BV
recurrence rate*
42/140 (30.0, 22.8–38.0–38) 37/133 (27.8, 20.7–35.9) 36/135 (26.7, 19.7–34.6) 115/408 (28.2, 24.0–32.7)
Hazard ratio for cumulative
M6 BV recurrence compared
to placebo{
1.09 (0.69–1.70) 1.03 (0.65–1.62)
Secondary Study Outcomes by Treatment Arm (n=408)*
Treatment Arms
Clindamycin n=140
(%, 95%CIs)
Probiotic n=133
(%, 95%CIs)
Placebo n=135
(%, 95%CIs)
Study Population n=408
(%, 95%CIs)
M1 abnormal flora
recurrence rate*
32/140 (22.9, 17.4–29.1) 29/133 (21.8, 15.4–29.4) 33/135 (24.4, 17.8–32.2) 94/408 (23.0, 19.1–27.3)
Hazard ratio for M1
abnormal flora recurrence
compared to placebo{
0.98 (0.60–1.62) 0.97 (0.59–1.60)
Cumulative 6-month
abnormal flora recurrence*
78/140 (55.7, 47.4–63.8) 70/133 (52.6, 44.1–61.0) 72/135 (53.3, 44.9–61.6) 220/408 (53.9, 49.1–58.7)
Hazard ratio for M6
abnormal flora recurrence
compared to placebo{
1.00 (0.72–1.38) 0.96 (0.69–1.33)
M1=month one, M6=month 6,
{missing data included in the denominator in calculation of recurrence rates- month one data missing on 44 women equally distributed between treatment arms
(13,18,13) and month six data missing on 57 women equally distributed between treatment groups (14,22,21),
*chi square test for comparison of BV recurrence rates between the three treatment groups at month one (p=0.13) and month six (p=0.82) and for comparison of
abnormal flora recurrence rates between the three treatment groups at month one (p=0.87) and month six (p=0.87).
{All Hazard ratios at month one and six for BV and abnormal flora recurrence were adjusted for adherence to the vaginal product as indicated in the results.
doi:10.1371/journal.pone.0034540.t004
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BV on the Amsel criteria. In this trial, interim metronidazole use
for BV symptoms accompanied by intermediate vaginal flora
(n=17), or probable metronidazole use in the community without
Nugent score data (n=10), occurred in 27 participants over 6
months of follow-up, and did not differ by treatment group
(p=0.49). Participants were encouraged to contact us with interval
symptoms, to facilitate interim access and additional sample
collection; however, the inability to capture all clinically relevant
episodes of BV using the Nugent method may have under-
estimated the clinical recurrence rate in each arm by up to 4–8%.
Importantly, the aim of this study was not to determine the clinical
recurrence rate of BV, but to determine if the recurrence rates
differed between treatment groups, and participants with clinically
relevant symptoms not captured by the primary outcome measure
did not differ between treatment groups. Lastly, 408 (91%)
participants provided one or more Nugent scores following
treatment and contributed person-time to survival analyses.
However, the six month retention rate for the trial was 78%.
This 22% loss to follow-up over six months may have potentially
reduced our statistical power to detect a small treatment effect but
Figure 2. Probability of being free from BV recurrence over 6 months.
doi:10.1371/journal.pone.0034540.g002
Figure 3. Probability of being free from abnormal flora recurrence over 6 months.
doi:10.1371/journal.pone.0034540.g003
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groups.
The strengths of our trial include that it was a large RCT with
sufficient power to detect a clinically meaningful difference in
efficacy between the treatment groups. The groups were well-
balanced for demographic and behavioural characteristics at
baseline, and we collected detailed epidemiological data to
determine if behavioural characteristics are associated with
recurrence, which is the subject of future planned analyses. We
applied the gold standard Nugent method to all slides to ensure
generalizability of our findings, and have an ongoing quality
assurance programme to ensure consistency between our experi-
enced microscopists. We performed extended follow-up for six
months with frequent evaluations which would have detected early
non-sustained differences between the arms if they had occurred.
High levels of adherence were reported to oral and trial
medication.
This trial shows no additional benefit from combining oral
metronidazole with vaginal clindamycin cream or a commercially
available vaginal-L.acidophilus probiotic. Current internationally
recommended treatments are delivered as monotherapies, but
have not achieved high sustained cure rates whether used for a
week or in suppressive or periodic presumptive regimens. There is
a well-recognized need for more effective management of both
initial and recurrent BV, both to alleviate symptoms and to reduce
its adverse the sequelae. How integral behavioural factors are in
the development and recurrence of BV is still not completely
understood, and remains an important area of research to advance
our management of this common condition.
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